Q2 2026 Bruker Corp Earnings Call Transcript
Key Points
- Bruker Corp (BRKR) returned to organic revenue growth in Q2 2026, with a 2.8% increase year-over-year, or 3.4% excluding tariff refunds.
- Scientific instruments segment achieved 10% organic bookings growth, marking the fourth consecutive quarter with a book-to-bill ratio above 1.0.
- Strong demand in deep tech sectors, with semiconductor metrology and energy research both seeing over 50% organic order growth year-over-year.
- Non-GAAP gross margin expanded 350 basis points to 52.1%, and operating margin increased 510 basis points to 14.1%, driven by cost-saving actions and favorable mix.
- Non-GAAP EPS grew 53% year-over-year to $0.49, and the company is on track to deliver $140 million in annualized cost savings in 2026.
- Biopharma bookings grew over 20% in Q2, driven by demand for NMR, X-ray, and mass spectrometry solutions.
- The new operating structure is expected to drive an additional $20 million in cost reductions in fiscal year 2027.
- U.S. academic and government orders remained weak in Q2, with U.S. ACA-Gov revenues down more than $15 million year-over-year.
- Asia Pacific revenue declined in the low double-digits, including a low double-digit decline in China.
- Q2 organic revenue growth was at the low end of expectations, impacted by U.S. tariff refunds and a stronger U.S. dollar, totaling approximately 110 basis points.
- The company recorded a non-cash goodwill impairment charge of $135 million related to automation and spatial biology businesses.
- Approximately $20 million of Q3 revenue is expected to shift into Q4 due to semiconductor customer delivery requirements, impacting Q3 growth.
- First half 2026 organic revenue declined 0.8%, reflecting a 1.4% decline in scientific instruments.
- The company faces ongoing challenges in the U.S. academic market, with NIH outlays not yet translating into significant Q2 orders.
Good day and welcome to the Berger Corporation Second Quarter 2026 Earnings Conference Call.
All participants will be in listen-only mode.
Should you need assistance, please signal a conference specialist by pressing the star key followed by zero.
After today's presentation, there will be an opportunity to ask questions.
To ask a question, you may press star then one on your telephone keypad.
To withdraw your question, please press star then two.
Please note this event is being recorded.
I would now like to hand the call over to Joe Koska, Director of Investor Relations. Please go ahead.
Good morning. I would like to welcome everyone to the Bruker Corporation's second quarter 2026 earnings conference call.
My name is Joe Koska, and I am the Director of Bruker Investor Relations.
Joining me on today's call are our President and CEO, Frank Laukeen, and our EVP and CFO, Gerald Herman.
In addition to the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
